YELLOW II Study: Reduction in Coronary Yellow Plaque, Lipids and Vascular Inflammation by Aggressive Lipid Lowering

Trial Profile

YELLOW II Study: Reduction in Coronary Yellow Plaque, Lipids and Vascular Inflammation by Aggressive Lipid Lowering

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Mar 2017

At a glance

  • Drugs Rosuvastatin (Primary)
  • Indications Coronary artery disease
  • Focus Biomarker; Pharmacodynamics
  • Acronyms YELLOW-II
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 27 Oct 2016 Results published in the Journal of the American College of Cardiology
    • 28 Oct 2015 Status changed from recruiting to completed as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top